Mayo researchers find that an investigational oral drug combo shows promise for newly diagnosed multiple myeloma

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology. Click here to read the full press release. ### Among the research institutions NCI funds across the United States, … Continue reading “Mayo researchers find that an investigational oral drug combo shows promise for newly diagnosed multiple myeloma”

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.

Click here to read the full press release.

###

NCI Comprehensive Cancer Center logoAmong the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply